Fig. 2.

Timeline of clinical history and response to radioablation followed by everolimus. A. Clinical history over time. B. Hypermetabolic malignancy in and adjacent to the liver, as observed by PET-CT in May 2014. The patient underwent radiofrequency ablation and radiation therapy to the liver in June 2014. Genomically-matched targeted treatment with everolimus (10 mg oral daily) begun in July 2014. Follow-up PET-CT scan in October 2014 demonstrated resolution of previous liver lesions but a worsening of left hydronephrosis.